Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03243331 · ClinicalTrials.gov registry record · Phase 1
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
A Phase 1 study, sponsored by Kathy Miller.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03243331 is a Phase 1 study that has completed, run by Kathy Miller. The registered enrollment target is 18 participants.
The verdict
NCT03243331, a Phase 1 study, has completed, sponsored by Kathy Miller.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Phase 1 study to evaluate the safety and effect of Gedatolisib and PTK7-ADC for the treatment of triple negative breast cancer
Interventions
- DRUG Gedatolisib
- DRUG PTK7-ADC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-01-19 |
| Est. Completion | 2020-05-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03243331
The ClinicalTrials.gov registry entry for NCT03243331 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kathy Miller, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gedatolisib is the first listed.
NCT03243331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03243331 about?
NCT03243331 is a clinical study titled "An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer". Phase 1 study to evaluate the safety and effect of Gedatolisib and PTK7-ADC for the treatment of triple negative breast cancer
What is the current status of trial NCT03243331?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-01-19. Estimated completion is 2020-05-27.
What interventions are being tested in trial NCT03243331?
The interventions under investigation include: Gedatolisib (DRUG), PTK7-ADC (DRUG).
Who is sponsoring clinical trial NCT03243331?
This trial is sponsored by Kathy Miller, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.